- Home
- SKLZ vs IVA Comparison
SKLZ vs IVA Comparison
Compare SKLZ & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKLZ
- IVA
- Stock Information
- Founded
- SKLZ 2012
- IVA 2011
- Country
- SKLZ United States
- IVA France
- Employees
- SKLZ N/A
- IVA N/A
- Industry
- SKLZ EDP Services
- IVA Biotechnology: Pharmaceutical Preparations
- Sector
- SKLZ Technology
- IVA Health Care
- Exchange
- SKLZ Nasdaq
- IVA Nasdaq
- Market Cap
- SKLZ 108.6M
- IVA 127.0M
- IPO Year
- SKLZ N/A
- IVA 2020
- Fundamental
- Price
- SKLZ $6.33
- IVA $2.84
- Analyst Decision
- SKLZ Buy
- IVA Strong Buy
- Analyst Count
- SKLZ 2
- IVA 4
- Target Price
- SKLZ $10.75
- IVA $13.25
- AVG Volume (30 Days)
- SKLZ 74.9K
- IVA 10.9K
- Earning Date
- SKLZ 03-13-2025
- IVA 03-26-2025
- Dividend Yield
- SKLZ N/A
- IVA N/A
- EPS Growth
- SKLZ N/A
- IVA N/A
- EPS
- SKLZ N/A
- IVA N/A
- Revenue
- SKLZ $106,198,000.00
- IVA $20,652,523.00
- Revenue This Year
- SKLZ N/A
- IVA N/A
- Revenue Next Year
- SKLZ $5.83
- IVA $197.46
- P/E Ratio
- SKLZ N/A
- IVA N/A
- Revenue Growth
- SKLZ N/A
- IVA N/A
- 52 Week Low
- SKLZ $4.33
- IVA $1.53
- 52 Week High
- SKLZ $7.48
- IVA $4.50
- Technical
- Relative Strength Index (RSI)
- SKLZ 52.55
- IVA 69.74
- Support Level
- SKLZ $6.10
- IVA $2.58
- Resistance Level
- SKLZ $6.72
- IVA $2.80
- Average True Range (ATR)
- SKLZ 0.24
- IVA 0.15
- MACD
- SKLZ -0.06
- IVA 0.04
- Stochastic Oscillator
- SKLZ 35.06
- IVA 81.31
About SKLZ Skillz Inc.
Skillz Inc is a mobile game development company. It is engaged in re-inventing competitive mobile gaming and thereby expanding the mobile gaming market. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The company's reportable business segments are; the Skillz segment and the Aarki segment. The majority of its revenue is generated from the Skillz segment which is an eSports gaming platform, enabling game developers to monetize their content through multi-player competition. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
About IVA Inventiva S.A. American Depository Shares
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.